Liang Cheng: Redefining Bladder Cancer Care with Urinary DNA Insights
Liang Cheng, Vice Chair for Translational Research at The Warren Alpert Medical School of Brown University, shared on LinkedIn:
“Happy Friday! I’m delighted to share our study – ‘Urinary Tumor DNA–based Liquid Biopsy in Bladder Cancer Management: A Systematic Review’, now available online. This work represents tremendous efforts of an amazing team of collaborators over the past year – Congratulations Joanne Lee, Andrea Necchi, Alessia Cimadamore, Philippe Spiess, Sinchita Roy-Chowdhuri and all!
Study Summary:
Urinary tumor DNA (utDNA) shows substantial promise in improving nearly all stages of bladder cancer (BCa) detection, treatment, and monitoring.
By retaining the low cost and noninvasiveness of urine cytology while replacing its suboptimal accuracy with precision that rivals – and often exceeds – cystoscopy and circulating tumor DNA (ctDNA) – based methods, utDNA offers a more comfortable, repeatable, and accurate approach to BCa detection.
Its superior sensitivity enables identification of both low-grade tumors and the earliest signs of recurrence, optimizing treatment planning and improving patient outcomes.
Beyond detection, utDNA provides valuable insights into tumor grade and stage, supporting informed treatment decisions, bladder preservation strategies, and the development of targeted immunotherapies.
With its high sensitivity, utDNA holds potential for screening, recurrence monitoring, treatment guidance, prognosis prediction, and minimal residual disease (MRD) detection. While its role in non-BCa malignancies remains underexplored, its advantages over ctDNA warrant further investigation.
Future research should compare standalone utDNA-based methods with combinations involving ctDNA, cystoscopy, or cytology, and explore integration with artificial intelligence – driven algorithms to further enhance personalized cancer care.
Current evidence positions utDNA as a promising biomarker to transform BCa management and surveillance strategies.
The paper is available here.”
Title: Urinary Tumor DNA–based Liquid Biopsy in Bladder Cancer Management: A Systematic Review
Authors: Joanne Lee, Fei Chen, Antonio Lopez-Beltran, Andrea Necchi, Alessia Cimadamore, Philippe E. Spiess, Roger Li, Sinchita Roy-Chowdhuri, Rodolfo Montironi, Dragan Golijanin, Claudio Luchini, Liang Cheng
More posts featuring Liang Cheng.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023